EN | UA
EN | UA

Help Support

Back

Colloidal bismuth pectin vs. bismuth potassium citrate quadruple therapy for H. pylori elimination

Helicobacter pylori Helicobacter pylori
Helicobacter pylori Helicobacter pylori

Safety and effectiveness of colloidal bismuth pectin (CBP) quadruple therapy and bismuth potassium citrate (BPC) quadruple therapy were contrasted for Helicobacter pylori (H. pylori) elimination in a multicenter, non-inferiority, double-blind, randomized clinical trial.

See All

Key take away

Both colloidal bismuth pectin and bismuth potassium citrate quadruple therapy are effective, safe and have good compliance in H. pylori management.

Background

Safety and effectiveness of colloidal bismuth pectin (CBP) quadruple therapy and bismuth potassium citrate (BPC) quadruple therapy were contrasted for Helicobacter pylori (H. pylori) elimination in a multicenter, non-inferiority, double-blind, randomized clinical trial.

Method

People with H. pylori infection and no history of elimination received one of four treatments for 14 days: 1 g Amoxicillin two times a day, 500 mg Tetracycline thrice a day, 20 mg Esomeprazole two times a day plus 200 mg CBP thrice a day, or BPC 240 mg two times a day. Minimum four weeks following therapy, the elimination rate was assessed by 13C-urea breath tests.

Result

Out of 406 patients, 339 individuals were randomized. According to intention-to-treat analysis, the cure rates (primary outcome) of CBP and BPC quadruple therapy is depicted in Table 1:

In the intention-to-treat and per-protocol analyses, CBP quadruple therapy exhibited non-inferiority to BPC quadruple therapy. There were no differences between both groups in the frequency of adverse events and compliance.

Conclusion

In the first-line treatment of H. pylori, both CBP and BPC quadruple therapy for 14 days offered high effectiveness, good compliance and had a favorable safety profile.

Source:

Helicobacter

Article:

Colloidal bismuth pectin-containing quadruple therapy as the first-line treatment of Helicobacter pylori infection: A multicenter, randomized, double-blind, non-inferiority clinical trial

Authors:

Yong Xie et al.

Comments (0)

You want to delete this comment? Please mention comment Invalid Text Content Text Content cannot me more than 1000 Something Went Wrong Cancel Confirm Confirm Delete Hide Replies View Replies View Replies en ru
Try: